Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 89   

Articles published

ARNA 1.67 -0.01 (-0.60%)
price chart
Arena Pharmaceuticals Inc Realized Volatility Hits An Inflection Point
This is a proprietary realized volatility rating created by Capital Market Laboratories (CMLviz) based on a large number of data interactions for Arena Pharmaceuticals Inc (NASDAQ:ARNA) . We examine the little used gem of daily stock volatilty over a ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) added about 5.1 percent in value ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is expected to announce second quarter financial results estimated on August 03, 2016.
The Insider Activity Don't Lie: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)  Review Fortune
Review Analyst's saying: AbbVie Inc. (NYSE:ABBV) , Arena Pharmaceuticals ...  Is stories
Analyst's Stocks Ratings Trend: GlaxoSmithKline PLC (NYSE:GSK) , Arena ...
On 7/27/2016, shares of GlaxoSmithKline PLC (NYSE:GSK) rose +2.17% in trading session and finally closed at $45.12. The company most recent volume stood at 6.01 million shares as compared to average volume of 3.51 million shares. Over the one year ...
Arena Pharma stock rises 8.8% after weight-loss drug is approved
Arena Pharmaceuticals Inc. ARNA, -5.62% shares rose 8.8% in pre-market trade Tuesday after the company said its weight-loss drug with Eisai Inc. 4523, +0.46% received Food and Drug Administration approval.
Biotech Stocks Worth Chasing: Celgene Corp. (CELG), Arena Pharmaceuticals, Inc ...
Arena Pharmaceuticals, Inc. (ARNA) recently recorded 0.6 percent change and currently at $1.67 is 28.46 percent away from its 52-week low and down -59.95 percent versus its peak.
Scorching Hot Biotech Stocks Tape: Zafgen, Inc. (ZFGN), Arena Pharmaceuticals ...
Zafgen, Inc. (ZFGN) ended last trading session with a change of -1.34 percent. It trades at an average volume of 618.36K shares versus 3.47M shares recorded at the end of last trading session.
Top Earnings to Watch for: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) decreased -1.75% to reach at the trading price of $1.68 as it is set to share its next quarterly earnings on August 03, 2016.
Eisai Inc. and Arena Pharmaceuticals Announce FDA Approval of BELVIQ XR ...
WOODCLIFF LAKE, N.J. and SAN DIEGO, July 19, 2016 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the U.S.
Arena - Belviq Scripts Start Q3 In Tough Shape  Seeking Alpha
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock rises 8.8% after weight-loss ...  Benchmark Monitor
Arena Pharmaceuticals Inc Stock Technicals at Critical Inflection Point
This is a technical analysis stock rating for Arena Pharmaceuticals Inc (NASDAQ:ARNA) . The company has a three bull technical rating which indicates an inflection point.
Company Update (NASDAQ:ARNA): Arena Pharmaceuticals, Inc. and Eisai Inc ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Eisai Inc. announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) has granted regulatory approval of the chronic weight management agent VENESPRI´┐Ż(lorcaserin HCl: ...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) Receives Consensus Rating of " ...  BBNS
Arena Pharmaceuticals boosted as obesity drug gets Mexican approval  Proactive Investors USA & Canada